|
1
|
Harbeck N and Gnant M: Breast cancer.
Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, McCarron P and Parkin DM: The
changing global patterns of female breast cancer incidence and
mortality. Breast Cancer Res. 6:229–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pogoda K, Niwińska A, Murawska M and
Pieńkowski T: Analysis of pattern, time and risk factors
influencing recurrence in triple-negative breast cancer patients.
Med Oncol. 30:3882013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang F, Liang H, Li Z and Huang P: JAK3
is a potential biomarker and associated with immune infiltration in
kidney renal clear cell carcinoma. Int Immunopharmacol.
86:1067062020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Halvorsen AR, Helland Å, Gromov P,
Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL,
Gromova I and Haakensen VD: Profiling of microRNAs in tumor
interstitial fluid of breast tumors-a novel resource to identify
biomarkers for prognostic classification and detection of cancer.
Mol Oncol. 11:220–234. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Madhavan D, Cuk K, Burwinkel B and Yang R:
Cancer diagnosis and prognosis decoded by blood-based circulating
microRNA signatures. Front Genet. 4:1162013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Christou N, Meyer J, Popeskou S, David V,
Toso C, Buchs N, Liot E, Robert J, Ris F and Mathonnet M:
Circulating tumour cells, circulating tumour DNA and circulating
tumour miRNA in blood assays in the different steps of colorectal
cancer management, a review of the evidence in 2019. Biomed Res
Int. 2019:59530362019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang K, Wu X, Wang J, Lopez J, Zhou W,
Yang L, Wang SE, Raz DJ and Kim JY: Circulating miRNA profile in
esophageal adenocarcinoma. Am J Cancer Res. 6:2713–2721.
2016.PubMed/NCBI
|
|
11
|
Liu X, Zhang H, Qin S, Wang Q, Yang X and
Wang K: Optical fiber amplifier for quantitative and sensitive
point-of-care testing of myoglobin and miRNA-141. Biosens
Bioelectron. 129:87–92. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Imaoka H, Toiyama Y, Fujikawa H, Hiro J,
Saigusa S, Tanaka K, Inoue Y, Mohri Y, Mori T, Kato T, et al:
Circulating microRNA-1290 as a novel diagnostic and prognostic
biomarker in human colorectal cancer. Ann Oncol. 27:1879–1886.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Toiyama Y, Takahashi M, Hur K, Nagasaka T,
Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21
as a diagnostic and prognostic biomarker in colorectal cancer. J
Natl Cancer Inst. 105:849–859. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhagirath D, Yang TL, Bucay N, Sekhon K,
Majid S, Shahryari V, Dahiya R, Tanaka Y and Saini S: microRNA-1246
Is an exosomal biomarker for aggressive prostate cancer. Cancer
Res. 78:1833–1844. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Z, Zhou L, Lin C, Pan X, Xie J, Zhao L,
Quan J, Xu J, Guan X, Xu W, et al: miR-302b regulates cell
functions and acts as a potential biomarker to predict recurrence
in bladder cancer. Life Sci. 209:15–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao C, Ling X, Li X, Hou X and Zhao D:
MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast
cancer by directly targeting RHBDD1. Breast Cancer. 26:817–825.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee HS, Kundu J, Kim RN and Shin YK:
Transducer of ERBB2.1 (TOB1) as a tumor suppressor: A mechanistic
perspective. Int J Mol Sci. 16:29815–29828. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kundu J, Wahab SM, Kundu JK, Choi YL,
Erkin OC, Lee HS, Park SG and Shin YK: Tob1 induces apoptosis and
inhibits proliferation, migration and invasion of gastric cancer
cells by activating Smad4 and inhibiting β-catenin signaling. Int J
Oncol. 41:839–848. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiao Y, Sun KK, Zhao L, Xu JY, Wang LL and
Fan SJ: Suppression of human lung cancer cell proliferation and
metastasis in vitro by the transducer of ErbB-2.1 (TOB1). Acta
Pharmacol Sin. 33:250–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu D, Zhou W, Wang S, Zhou Z, Wang S and
Chen L: Tob1 enhances radiosensitivity of breast cancer cells
involving the JNK and p38 pathways. Cell Biol Int. 39:1425–1430.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cioffi M, Trabulo SM, Vallespinos M, Raj
D, Kheir TB, Lin ML, Begum J, Baker AM, Amgheib A, Saif J, et al:
The miR-25-93-106b cluster regulates tumor metastasis and immune
evasion via modulation of CXCL12 and PD-L1. Oncotarget.
8:21609–21625. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sárközy M, Kahán Z and Csont T: A myriad
of roles of miR-25 in health and disease. Oncotarget.
9:21580–21612. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Meng X, Li H, Liu W, Shen S and
Gao Z: MicroRNA-25 expression level is an independent prognostic
factor in epithelial ovarian cancer. Clin Transl Oncol. 16:954–958.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wen Y, Han J, Chen J, Dong J, Xia Y, Liu
J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early
biomarkers for detecting hepatocellular carcinoma. Int J Cancer.
137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jia Y, Lu H, Wang C, Wang J and Zhang C,
Wang F and Zhang C: miR-25 is upregulated before the occurrence of
esophageal squamous cell carcinoma. Am J Transl Res. 9:4458–4469.
2017.PubMed/NCBI
|
|
26
|
Chang JT, Wang F, Chapin W and Huang RS:
Identification of MicroRNAs as breast cancer prognosis markers
through the cancer genome atlas. PLoS One. 11:e01682842016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen H, Pan H, Qian Y, Zhou W and Liu X:
miR-25-3p promotes the proliferation of triple negative breast
cancer by targeting BTG2. Mol Cancer. 17:42018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zou X, Xia T, Li M, Wang T, Liu P, Zhou X,
Huang Z and Zhu W: MicroRNA profiling in serum: Potential
signatures for breast cancer diagnosis. Cancer Biomark. 30:41–53.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dyer BW, Ferrer FA, Klinedinst DK and
Rodriguez R: A noncommercial dual luciferase enzyme assay system
for reporter gene analysis. Anal Biochem. 282:158–161. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grentzmann G, Ingram JA, Kelly PJ,
Gesteland RF and Atkins JF: A dual-luciferase reporter system for
studying recoding signals. RNA. 4:479–486. 1998.PubMed/NCBI
|
|
32
|
Cortez MA, Welsh JW and Calin GA:
Circulating microRNAs as noninvasive biomarkers in breast cancer.
Recent Results Cancer Res. 195:151–161. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mens MMJ and Ghanbari M: Cell cycle
regulation of stem cells by MicroRNAs. Stem Cell Rev Rep.
14:309–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qi Y, Wang X, Kong X, Zhai J, Fang Y, Guan
X and Wang J: Expression signatures and roles of microRNAs in
inflammatory breast cancer. Cancer Cell Int. 19:232019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Z, Lin C, Zhao L, Zhou L, Pan X, Quan
J, Peng X, Li W, Li H, Xu J, et al: Oncogene miR-187-5p is
associated with cellular proliferation, migration, invasion,
apoptosis and an increased risk of recurrence in bladder cancer.
Biomed Pharmacother. 105:461–469. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olejniczak M, Kotowska-Zimmer A and
Krzyzosiak W: Stress-induced changes in miRNA biogenesis and
functioning. Cell Mol Life Sci. 75:177–191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Singh SK, Pal Bhadra M, Girschick HJ and
Bhadra U: MicroRNAs-micro in size but macro in function. FEBS J.
275:4929–4944. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Armand-Labit V and Pradines A: Circulating
cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts.
8:61–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
10:10513–10518. 2008. View Article : Google Scholar
|
|
40
|
Li Q, Liu M, Ma F, Luo Y, Cai R, Wang L,
Xu N and Xu B: Circulating miR-19a and miR-205 in serum may predict
the sensitivity of luminal A subtype of breast cancer patients to
neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One.
9:e1048702014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shen L, Wan Z, Ma Y, Wu L, Liu F, Zang H
and Xin S: The clinical utility of microRNA-21 as novel biomarker
for diagnosing human cancers. Tumour Biol. 36:1993–2005. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gruszka R and Zakrzewska M: The oncogenic
relevance of miR-17-92 cluster and its paralogous miR-106b-25 and
miR-106a-363 clusters in brain tumors. Int J Mol Sci. 19:8792018.
View Article : Google Scholar
|
|
43
|
Wang C, Wang X, Su Z, Fei H, Liu X and Pan
Q: miR-25 promotes hepatocellular carcinoma cell growth, migration
and invasion by inhibiting RhoGDI1. Oncotarget. 6:36231–36244.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hua Y, Zhao K, Tao G, Dai C and Su Y:
miR-25 promotes metastasis via targeting FBXW7 in esophageal
squamous cell carcinoma. Oncol Rep. 38:3030–3038. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fujiwara T, Uotani K, Yoshida A, Morita T,
Nezu Y, Kobayashi E, Yoshida A, Uehara T, Omori T, Sugiu K, et al:
Clinical significance of circulating miR-25-3p as a novel
diagnostic and prognostic biomarker in osteosarcoma. Oncotarget.
8:33375–33392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Deng T, Yuan Y, Zhang C, Zhang C, Yao W,
Wang C, Liu R and Ba Y: Identification of circulating miR-25 as a
potential biomarker for pancreatic cancer diagnosis. Cell Physiol
Biochem. 39:1716–1722. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang X, Wu X, Yan L and Shao J: Serum
miR-103 as a potential diagnostic biomarker for breast cancer. Nan
Fang Yi Ke Da Xue Xue Bao. 32:631–634. 2012.(In Chinese).
PubMed/NCBI
|
|
48
|
Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG,
Ge SL and Zhang YK: Serum microRNA-195 is down-regulated in breast
cancer: A potential marker for the diagnosis of breast cancer. Mol
Biol Rep. 41:5913–5922. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li S, Yang X, Yang J, Zhen J and Zhang D:
Serum microRNA-21 as a potential diagnostic biomarker for breast
cancer: A systematic review and meta-analysis. Clin Exp Med.
16:29–35. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jinling W, Sijing S, Jie Z and Guinian W:
Prognostic value of circulating microRNA-21 for breast cancer: A
systematic review and meta-analysis. Artif Cells Nanomed
Biotechnol. 45:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hsieh TH, Hsu CY, Tsai CF, Long CY, Chai
CY, Hou MF, Lee JN, Wu DC, Wang SC and Tsai EM: miR-125a-5p is a
prognostic biomarker that targets HDAC4 to suppress breast
tumorigenesis. Oncotarget. 6:494–509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li J, Song ZJ, Wang YY, Yin Y, Liu Y and
Nan X: Low levels of serum miR-99a is a predictor of poor prognosis
in breast cancer. Genet Mol Res. 152016.doi:
10.4238/gmr.15038338.
|
|
53
|
Lin S, Zhu Q, Xu Y, Liu H, Zhang J, Xu J,
Wang H, Sang Q, Xing Q and Fan J: The role of the TOB1 gene in
growth suppression of hepatocellular carcinoma. Oncol Lett.
4:981–987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
O'Malley S, Su H, Zhang T, Ng C, Ge H and
Tang CK: TOB suppresses breast cancer tumorigenesis. Int J Cancer.
125:1805–1813. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Guo H, Ji F, Zhao X, Yang X, He J, Huang L
and Zhang Y: MicroRNA-371a-3p promotes progression of gastric
cancer by targeting TOB1. Cancer Lett. 443:179–188. 2019.
View Article : Google Scholar : PubMed/NCBI
|
